Baxter planning 1997 overseas launch of Sorin low-profile mechanical heart valve.
This article was originally published in The Gray Sheet
Executive Summary
BAXTER LAUNCH OF SORIN LOW-PROFILE MECHANICAL HEART VALVE IN 1997 will be accomplished through an agreement with Sorin Biomedica SpA announced Nov. 13. The deal, terms of which were not disclosed, gives the Edwards CVS division of Baxter's Cardiovascular Group exclusive worldwide distribution rights to a low-profile bileaflet mechanical heart valve to be manufactured by Sorin. The valve's design makes it "especially suitable" for use in conjunction with "minimally invasive heart valve implant techniques," Baxter says in a Nov. 13 press release.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.